Showing results (11-20 of 143) with videos related to
Sort By:
Pageof 15
Current Atherosclerosis Reports|March 28, 2008
Exenatide as a treatment for diabetes and obesity: implications for cardiovascular risk reductionDerek D Mafong, Robert R HenryDiabetologia|August 23, 2018
SGLT inhibitor adjunct therapy in type 1 diabetesRory J McCrimmon, Robert R HenryCurrent Hypertension Reports|January 17, 2009
The role of incretins in cardiovascular controlDerek D Mafong, Robert R HenryNature Reviews. Drug Discovery|May 29, 2010
SGLT2 inhibition--a novel strategy for diabetes treatmentEdward C Chao, Robert R HenryExpert Opinion on Pharmacotherapy|September 12, 2009
Pharmacotherapy of hyperglycemiaKristen M Kulasa, Robert R HenryDiabetes Care|June 12, 2016
Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying HypothesisSunder Mudaliar, Sindura Alloju, Robert R HenryEndocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|October 30, 2003
Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implicationsSunder Mudaliar, Anna R Chang, Robert R HenryDiabetes, Obesity & Metabolism|March 30, 2007
Adiponectin in health and diseaseDeborah K Oh, Theodore Ciaraldi, Robert R HenryEndocrinology and Metabolism Clinics of North America|July 21, 2004
Glitazones and the management of insulin resistance: what they do and how might they be usedDaniel Einhorn, Vanita R Aroda, Robert R HenryJournal of Diabetes and Its Complications|June 4, 2013
New options for the treatment of obesity and type 2 diabetes mellitus (narrative review)Robert R Henry, Robert Chilton, W Timothy GarveyPageof 15